Danaher (NYSE:DHR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday. The firm presently has a $112.00 target price on the conglomerate’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 13.54% from the company’s previous close.
According to Zacks, “Danaher has an excellent earnings history over the trailing four quarters, beating estimates all through. We are optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues. This apart, the company’s continuous introduction of products enables it to penetrate new markets and gain competitive edge in existing ones. Over the past six months, the stock has outperformed the industry average. However, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business might restrict growth, going forward. Moreover, weakness in industrial markets and stiff competition may also hurt the company's financials.”
Several other equities analysts also recently issued reports on DHR. Credit Suisse Group lifted their price objective on Danaher from $106.00 to $108.00 and gave the company an “outperform” rating in a research report on Tuesday, March 13th. Deutsche Bank dropped their target price on Danaher from $114.00 to $107.00 and set a “buy” rating for the company in a research report on Thursday, March 1st. Royal Bank of Canada restated a “hold” rating and set a $98.00 target price on shares of Danaher in a research report on Wednesday, January 31st. Stifel Nicolaus restated a “buy” rating and set a $110.00 target price on shares of Danaher in a research report on Friday, January 19th. Finally, Morgan Stanley boosted their target price on Danaher from $103.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $102.23.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the previous year, the company posted $1.05 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. sell-side analysts forecast that Danaher will post 4.38 EPS for the current fiscal year.
In related news, insider Rainer Blair sold 3,981 shares of Danaher stock in a transaction on Monday, February 26th. The stock was sold at an average price of $100.05, for a total transaction of $398,299.05. Following the completion of the sale, the insider now directly owns 49,751 shares of the company’s stock, valued at $4,977,587.55. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Walter G. Lohr sold 10,578 shares of Danaher stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $97.90, for a total value of $1,035,586.20. Following the sale, the director now directly owns 19,821 shares of the company’s stock, valued at $1,940,475.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 313,260 shares of company stock valued at $31,657,786. 12.20% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in the stock. North American Management Corp grew its stake in Danaher by 0.4% in the fourth quarter. North American Management Corp now owns 123,093 shares of the conglomerate’s stock valued at $11,426,000 after acquiring an additional 512 shares during the period. Chesley Taft & Associates LLC grew its stake in Danaher by 0.3% in the fourth quarter. Chesley Taft & Associates LLC now owns 161,450 shares of the conglomerate’s stock valued at $14,986,000 after acquiring an additional 519 shares during the period. FTB Advisors Inc. grew its stake in Danaher by 14.9% in the fourth quarter. FTB Advisors Inc. now owns 4,064 shares of the conglomerate’s stock valued at $386,000 after acquiring an additional 528 shares during the period. D.A. Davidson & CO. grew its stake in Danaher by 4.3% in the fourth quarter. D.A. Davidson & CO. now owns 13,374 shares of the conglomerate’s stock valued at $1,241,000 after acquiring an additional 548 shares during the period. Finally, Dorsey & Whitney Trust CO LLC grew its stake in Danaher by 10.2% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 6,077 shares of the conglomerate’s stock valued at $562,000 after acquiring an additional 560 shares during the period. 77.64% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/03/22/danaher-dhr-upgraded-to-buy-at-zacks-investment-research.html.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.